Yi Chen

State Key Laboratory Of Drug Research
Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Long-circulating enzyme-activated HSP90-targeted camptothecin derivatives.

Long-circulating enzyme-activated HSP90-targeted camptothecin derivatives.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: November 19, 2024

Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation.

Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation.

Journal: Signal transduction and targeted therapy

Published: November 20, 2023

Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.

Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.

Journal: Molecular cancer

Published: August 19, 2023

Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities.

Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities.

Journal: European journal of medicinal chemistry

Published: June 05, 2023

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK.

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK.

Journal: Frontiers in pharmacology

Published: October 15, 2022

Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.

Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.

Journal: Molecular cancer

Published: August 18, 2021

Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma.

Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma.

Journal: Cancer letters

Published: June 30, 2021

Cost-effectiveness analysis of a community-based colorectal cancer screening program in Shanghai, China.

Cost-effectiveness analysis of a community-based colorectal cancer screening program in Shanghai, China.

Journal: Journal of digestive diseases

Published: December 23, 2020

Correction: Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation.

Correction: Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation.

Journal: Oncotarget

Published: February 21, 2020

Erratum to Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer.

Erratum to Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer.

Journal: Cancer biology & medicine

Published: January 08, 2020

Correction to Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma.

Correction to Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma.

Journal: Molecular pharmaceutics

Published: December 06, 2019

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.

Journal: Molecular cancer

Published: November 26, 2019

Showing 1-12 of 34

Last Updated: 09/26/2026